DLTs in the phase 1b study
| Chidamide dose | Patients treated (n) | DLT (n) | Toxicity | Best response |
|---|---|---|---|---|
| 15 mg biw | 6 | 1 | Grade 3 pulmonary infection | 2CR, 1PR |
| 20 mg biw1 | 6 | 1 | Grade 4 neutropenia with G-CSF support | 2CR |
| 25 mg biw | 3 | 2 | Grade 4 neutropenia with G-CSF support | 2PR |
DLT, dose limited toxicity; CR, complete response; PR, partial response; G-CSF, granulocyte colony-stimulating factor.
1Maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D).